Vapotherm, Inc. (VAPO)
| Market Cap | 76.24M |
| Revenue (ttm) | 102.61M |
| Net Income (ttm) | -72.33M |
| Shares Out | 26.56M |
| EPS (ttm) | -2.78 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 252,760 |
| Open | 3.05 |
| Previous Close | 2.99 |
| Day's Range | 2.86 - 3.18 |
| 52-Week Range | 2.46 - 31.87 |
| Beta | -0.36 |
| Analysts | Buy |
| Price Target | 5.61 (+95.5%) |
| Earnings Date | Aug 8, 2022 |
About VAPO
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companio... [Read more...]
Financial Performance
In 2021, Vapotherm's revenue was $113.29 million, a decrease of -9.89% compared to the previous year's $125.73 million. Losses were -$59.80 million, 16.1% more than in 2020.
Financial StatementsAnalyst Forecast
According to 10 analysts, the average rating for VAPO stock is "Buy." The 12-month stock price forecast is 5.61, which is an increase of 95.47% from the latest price.
News
Vapotherm to Participate in the William Blair 42nd Annual Growth Stock Conference
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm (VAPO) Reports Q1 Loss, Tops Revenue Estimates
Vapotherm (VAPO) delivered earnings and revenue surprises of -38.10% and 1.89%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm Reports First Quarter 2022 Financial Results
EXETER, N--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced first quarter 2022 financial results. First Quarter 2022 Summary Total revenue for the first qua...
Vapotherm to Report First Quarter 2022 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapoth...
Vapotherm (VAPO) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
Vapotherm (VAPO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vapotherm Issues Q1 FY22 Sales Guidance Below Expectations, Pulls FY22 Outlook
Vapotherm Inc (NYSE: VAPO) expects Q1 FY22 sales of $20.5 million - $21.5 million, lower than $32.3 million in Q1 FY21 and the consensus of $25.78 million. Vapotherm also announced the withdrawal of its...
Vapotherm Announces Preliminary Revenue for First Quarter of 2022 and Withdraws 2022 Annual Guidance
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), today announced preliminary unaudited revenue for the quarter ended March 31, 2022. The Company also announced...
Vapotherm Launches Strategic Partnership with Carnegie Mellon University to Deliver a Tailored Artificial Intelligenc...
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), a global medical technology company focused on developing innovative, non-invasive technologies and digital health solutions for respiratory ...
Vapotherm (VAPO) Reports Q4 Loss, Tops Revenue Estimates
Vapotherm (VAPO) delivered earnings and revenue surprises of -14.52% and 2.04%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm Reports Fourth Quarter and Fiscal Year 2021 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its innovative, comfo...
Vapotherm to Report Fourth Quarter and Full Year 2021 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its innovative, comfor...
Vapotherm Reports Preliminary Fourth Quarter and Full Year 2021 Revenue Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its innovative, comfo...
Vapotherm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Vapotherm (VAPO) Reports Q3 Loss, Tops Revenue Estimates
Vapotherm (VAPO) delivered earnings and revenue surprises of -4.00% and 17.05%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm Reports Third Quarter 2021 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company, today announced third quarter 2021 financial results. Third Quarter 2021...
Earnings Preview: Vapotherm
Vapotherm (NYSE:VAPO) is set to give its latest quarterly earnings report on Wednesday, 2021-11-03. Here's what investors need to know before the announcement.
Earnings Preview: Vapotherm (VAPO) Q3 Earnings Expected to Decline
Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Vapotherm to Report Third Quarter 2021 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapoth...
Vapotherm Raises Annual Sales Outlook Amid Surge In COVID-19 Cases
Vapotherm Inc (NYSE: VAPO) expects FY21 revenue of at least $102 million, an increase of $17 million over the low end of previous guidance of $85 million - $91 million. Related Content: FDA Gives 510(...
Vapotherm Increases Fiscal Year 2021 Revenue Outlook and Announces Expansion of Production Capacity
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), today updated its fiscal year 2021 revenue expectations and announced it will expand its disposables productio...
FDA Gives 510(K) Nod To Vapotherm's Next-Gen High-Velocity Therapy
The FDA has granted 510(k) clearance to Vapotherm Inc's (NYSE:VAPO) HVT (high-velocity therapy) 2.0. Vapotherm high-velocity therapy is mask-free noninvasive ventilatory support and is a front-line tool...
Vapotherm Announces FDA 510(k) Clearance for HVT 2.0 Next Generation Platform
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), today announced it has received 510(k) clearance from the US Food and Drug Administration for HVT 2.0. This n...
Vapotherm (VAPO) Reports Q2 Loss, Tops Revenue Estimates
Vapotherm (VAPO) delivered earnings and revenue surprises of -4.69% and 13.45%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Vapotherm Reports Second Quarter 2021 Financial Results
EXETER, N.H.--(BUSINESS WIRE)--Vapotherm, Inc. (NYSE: VAPO), (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Vapot...
Analysts Estimate Vapotherm (VAPO) to Report a Decline in Earnings: What to Look Out for
Vapotherm (VAPO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.